New blood thinner vicagrel tested against clopidogrel in healthy volunteers
NCT ID NCT07067775
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested two blood-thinning drugs, vicagrel and clopidogrel, in 18 healthy adults with a specific gene type (CYP2C19 normal metabolizers). The goal was to compare how the body absorbs and processes each drug. Researchers measured drug levels in the blood and their effects on clotting. This is a first step to see if vicagrel might work better than the standard drug clopidogrel.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vicagrel and clopidogrel
What this could lead to
If vicagrel shows better absorption or action than clopidogrel, it could lead to a more effective anti-clotting drug for heart patients.
What could go wrong
This is a very early, small study in 18 healthy people, not patients. Results may not predict real-world benefits or safety in those with heart conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, China